It’s a new study from A U.S. study that shows a widely-used osteoporosis drug Raloxifene can protect postmenopausal women from breast cancer as effectively as long-prescribed breast cancer drug Tamoxifen with fewer side effects. Both Tamoxifen and Raloxifene act like estrogen hormone in some tissues, named as “selective estrogen response modulators” but like an anti-estrogen in others.
By acting like an estrogen in uterus and bloodstream, Tamoxifen is linked to rare but serious side effects, including increased risk of uterine cancers and blood clots. In comparison, Raloxifene, a close chemical relative to Tamoxifen, causes 36 percent fewer uterine cancers and 29 percent fewer blood clots.
The government Study of Tamoxifen and Raloxifene (STAR) involving 19,000 women shows that taking either drug daily for up to five years can reduce chances of developing invasive breast cancer by half in high-risk women, the National Cancer Institute said Monday in a statement.
Researchers said Raloxifene offers a new way of women health products to protect postmenopausal women from breast cancer. Tamoxifen, sold by AstraZeneca Plc under the brand name of Nolvadex, had for decades been the only drug to cut breast cancer risk in postmenopausal women.
Eli Lilly and Co’s Raloxifene has been sold under the brand name of Evista. The company said it would seek U.S. Food and Drug Administration’s approval to market Evista both for preventing breast cancer and bone-thinning osteoporosis, another common disease after menopause.
Related Post :
Knowing Women Breast Cancer Well
Breast Cancer on Teenage Girls
Source: Xinhua
Osteoporosis Medicine Found To Prevent Breast Cancer posted under
Women Health. Follow any responses to this entry when people .You can
leave a response, or
trackback from your own site.
Women Lifestyle
